Bioequivalence study of rimegepant Zydis® ODT formulation

Trial Profile

Bioequivalence study of rimegepant Zydis® ODT formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, expanded data will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting 2018.
    • 08 Mar 2018 New trial record
    • 01 Mar 2018 Pre-specified primary analysis from this trial presented in a Biohaven Pharmaceutical Holding Company Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top